KOL Perspectives: Biomarker Potential of Type I IFN Gene Signature in Lupus
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
› The briefing includes analysis of KOL opinion on the following topic areas:
– Awareness of biomarkers and predictors of disease activity in lupus
– Usefulness of the type I IFN signature test to identify patients who are most likely to respond to IFN-targeting therapies
– Impact of availability of a biomarker on willingness to prescribe a therapy
– Implementing a potential IFN biomarker test in clinical practice
– Willingness to prescribe anifrolumab to patients who do not display the interferon biomarker
– Barriers to using IFN signature test to stratify patients in clinical practice
– Impact of data suggesting that high IFN gene expression is closely associated with SLE on opinion of
anifrolumab’s efficacy
› Impact of data suggesting that high IFN gene expression is more closely associated with LN than IFN on
opinion of anifrolumab’s efficacy
Scope
› The insight briefing is based on Sociable Pharma’s analysis of primary research with our lupus key opinion leaders (KOLs)
› In total, we conducted interviews with 14 KOLs:
– Seven Europe-based & seven US-based
– Interviews performed in December 2017
> KOL data is analyzed to produce:
– Charts summarizing KOL opinions
– Chart call-outs of key information & details
– KOL quotes
– Summary of KOL reporting trends
– Insight from Sociable Pharma's analysts
Key Highlights
Majority of KOLs use complement & anti-DNA to monitor disease activity in clinical practice, while most are aware of the type I IFN signature test
Most KOLs flagged that the type I IFN signature test will be useful to stratify patients most likely to respond to type I IFN-targeting therapies
Most KOLs agreed that the availability of a biomarker would strongly influence their willingness to prescribe a therapy such as anifrolumab
Reasons to Buy
Combines Qualitative & semi-quantitative insight from key opinion leaders on " Biomarker Potential of Type I IFN Gene Signature in Lupus "
Includes insight & recommendations from our disease-specific healthcare analysts
Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of Lupus
Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion
Table of Contents
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.